These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11602042)

  • 21. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
    Pillay D; Walker AS; Gibb DM; de Rossi A; Kaye S; Ait-Khaled M; Muñoz-Fernandez M; Babiker A
    J Infect Dis; 2002 Sep; 186(5):617-25. PubMed ID: 12195348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
    Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
    Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.
    Sullivan AK; Nelson MR; Shaw A; Moyle GJ; Mandalia S; Gazzard BG; Asboe D
    HIV Clin Trials; 2000; 1(1):7-12. PubMed ID: 11590484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
    Clotet B; Ruiz L; Martinez-Picado J; Negredo E; Hill A; Popescu M
    HIV Clin Trials; 2002; 3(4):316-23. PubMed ID: 12187506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG; Hellmann NS; Grant RM; Parkin NT; Petropoulos CJ; Becker M; Symonds W; Chesney M; Volberding PA
    J Infect Dis; 1999 Jun; 179(6):1375-81. PubMed ID: 10228057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
    Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
    Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
    Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
    Saah AJ; Haas DW; DiNubile MJ; Chen J; Holder DJ; Rhodes RR; Shivaprakash M; Bakshi KK; Danovich RM; Graham DJ; Condra JH
    J Infect Dis; 2003 Apr; 187(7):1157-62. PubMed ID: 12660932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
    Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.